Poolbeg Pharma Performance dei guadagni passati
Il passato criteri di controllo 0/6
Poolbeg Pharma has been growing earnings at an average annual rate of 10.5%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually.
Informazioni chiave
10.5%
Tasso di crescita degli utili
10.5%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 14.1% |
| Tasso di crescita dei ricavi | n/a |
| Rendimento del capitale proprio | -35.2% |
| Margine netto | n/a |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth
Aug 20
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Feb 16We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Oct 05We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Jun 01Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Jul 12Ripartizione dei ricavi e delle spese
Come Poolbeg Pharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -4 | 4 | 2 |
| 31 Mar 24 | 0 | -4 | 4 | 2 |
| 31 Dec 23 | 0 | -4 | 3 | 2 |
| 30 Sep 23 | 0 | -4 | 3 | 2 |
| 30 Jun 23 | 0 | -5 | 3 | 2 |
| 31 Mar 23 | 0 | -5 | 3 | 2 |
| 31 Dec 22 | 0 | -5 | 3 | 2 |
Guadagni di qualità: POLB is currently unprofitable.
Margine di profitto in crescita: POLB is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Insufficient data to determine if POLB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerare la crescita: Unable to compare POLB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: POLB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).
Rendimento del capitale proprio
ROE elevato: POLB has a negative Return on Equity (-35.17%), as it is currently unprofitable.